Table 2.

Analysis of Factors Affecting CMV Reactivation

	Univariate		Multivariate
	OR (95% CI)	P-value	OR (95% CI)	P-value
Serogroup
R−/D+	1.0 (reference group)	N/A	1.0 (reference group)	N/A
R+/D+	10.3 (2.1–50.3)	.004*	23.8 (2.8–202.6)	.004*
R+/D−	11.8 (2.4–58.9)	.003*	25.7 (3.0–222.2)	.003*
Age >55	1.5 (.70–3.1)	.319	ND
Disease type
MDS	1.0 (reference group)	N/A	1.0 (reference group)	N/A
CML/CLL	1.8 (.50–6.7)	.368	3.4 (.77–14.5)	.106
NHL/HD	2.4 (.73–7.6)	.153	4.9 (1.2–119.1)	.023*
ALL/AML	5.5 (1.6–18.1)	.006*	9.7 (2.5–38.3)	.001*
Disease status
Remission	1.0 (reference group)	N/A	ND
Partial remission	.93 (.40–2.1)	.865	ND
Relapse	.45 (.16–1.3)	.133	ND
Donor type
MRD	1.0 (reference group)	N/A	ND	N/A
Haplo/PMRD	3.4 (.64–18.2)	.151	ND
URD	2.2 (1.0–4.8)	.048*	ND
aGVHD	4.5 (.93–21.3)	.062	ND
aGVHD (>1)	4.1 (.46–36.2)	.204	ND
Steroid use	2.2 (.79–6.2)	.132	ND
Chimerism >95% (d90)	1.1 (.50–2.2)	.892	ND

CI indicates confidence interval; OR, odds ratio; aGVHD, acute graft-versus-host disease; URD, unrelated donor; MRD, matched related donor; PMRD, partially matched related donor; MDS myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; HD, Hodgkin disease; NHL, non-Hodgkin lymphoma; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia.

In a univariate logistic regression, CMV seropositivity group (R−/D+, R+/D+, or R+/D−), underlying disease, and donor type were all associated with an increased likelihood of CMV reactivation (P < .050). A trend toward increased reactivation was seen with steroid use and aGVHD. Multivariate analysis demonstrated that only CMV seropositivity group and disease type were associated with increased odds of reactivation; adjusted ORs are shown for the variables included in this analysis, ND indicates multivariable analysis was not done.

^*Statistically significant results compared to relevant reference group (P < .050).